This study is a Phase 1/2, open-label clinical trial to test an experimental treatment called QEL-005 in adults with two autoimmune conditions: diffuse cutaneous systemic sclerosis (dcSSc) and difficult-to-treat rheumatoid arthritis (D2TRA). The main goals are to find out whether QEL-005 is safe, how well people tolerate it, and whether it may help reduce disease activity or improve symptoms. QEL-005 is made from a participant's own white blood cells (autologous cells). These cells are collected and then changed in a laboratory using genetic methods to create specialized immune cells called CAR-T regulatory cells that target a protein on B cells called CD19. These modified cells are then given back to the participant by intravenous (IV) infusion. To take part, eligible participants will first have a procedure called leukapheresis, where some of their white blood cells are removed from the blood. The study team will use these cells to manufacture QEL005. After QEL005 is ready, participants will receive an IV infusion of their modified cells, stay in hospital overnight for monitoring, and will then be followed closely in the clinic. Throughout the trial, participants will have regular safety checks, which may include blood tests, imaging scans, questionnaires about symptoms and daily functioning, and biopsies taken from involved tissues, to help understand how QEL005 is working in the body. Detailed follow up will be for 1 year after QEL-005 infusion, and there is long-term follow up for a total of 15 years, which is standard for cell therapies. The information from this Phase 1/2 study will help determine an appropriate dose and dosing schedule of QEL005 for future studies.
This is a single-arm, open label, multicentre, Phase 1/2, first in human study of QEL005 in adult participants with diffuse cutaneous systemic sclerosis (dcSSc) or difficult to treat rheumatoid arthritis (D2TRA). QEL005 is an autologous chimeric antigen receptor regulatory T-cell (CAR-Treg) therapy directed against the CD19 marker found on B cells. The primary objective of this study is to evaluate the safety and tolerability of single IV infusions of QEL005 across different dose levels in participants with dcSSc or D2TRA. Secondary and exploratory objectives include assessment of preliminary clinical efficacy (for example, changes in disease activity scores, skin involvement, or joint symptoms, as appropriate for each disease) and evaluation of biological activity (including effects on B cell populations, immune biomarkers, and other laboratory measures). The study uses a dose escalation phase then a dose expansion phase. In the dose escalation phase, sequential cohorts of participants receive increasing doses of QEL005 under close safety monitoring. Safety assessments include recording of adverse events, vital signs and laboratory abnormalities. QEL005 is manufactured from autologous leukapheresis material obtained at baseline. Participants undergo leukapheresis for collection of peripheral blood mononuclear cells, which are then genetically modified ex vivo to express a CD19directed CAR-T regulatory cell. Over the course of the trial, participants will attend scheduled visits for clinical evaluations, laboratory tests, imaging studies, and patient reported outcome questionnaires, as well as tissue biopsies, to characterize the safety profile and to explore pharmacodynamic and immunologic effects of QEL005. There are detailed assessments over the first year following QEL-005 infusion, and then additional long-term follow up for 15 years, standard for cell therapy trials. Data from this Phase 1/2 trial will inform the recommended dose, regimen, and patient population for subsequent studies of QEL005 in autoimmune diseases.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
QEL-005 is an autologous cell therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against the B cell marker CD19. Treatment will be given via an IV infusion.
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
NOT_YET_RECRUITINGLeeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
NOT_YET_RECRUITINGGuy's & St Thomas NHS Foundation Trust
London, United Kingdom
NOT_YET_RECRUITINGRoyal Free London NHS Foundation Trust
London, United Kingdom
NOT_YET_RECRUITINGNewcastle Upon Tyne NHS Foundation Trust
Newcastle, United Kingdom
RECRUITINGUniversity of Oxford - The Kennedy Institute
Oxford, United Kingdom
RECRUITINGD2TRA & SSc: Incidence of Protocol-Defined Dose Limiting Toxicities (DLTs) to Assess Safety and Tolerability (Dose Escalation Phase Only)
Assessment of safety and tolerability of QEL-005 during the Dose Escalation Phase, as measured by the incidence of protocol-defined dose limiting toxicities (DLTs).
Time frame: up to 28 days post-infusion
D2TRA & SSc: Incidence and grade of treatment-emergent adverse events (TEAEs), adverse events (AEs) and adverse events of special interest (AESIs)
Assessment of safety and tolerability of D2TRA \& SSc through the collection and evaluation of the incidence and severity grades of all TEAEs, AEs, and AESIs using the Common Terminology Criteria for Adverse Events (CTCAE)
Time frame: From time of signing the informed consent form (ICF) through to week 52
D2TRA & SSc: Incidence of clinically significant abnormalities in safety laboratory parameters, electrocardiogram (ECG) findings, and vital signs
Evaluation of safety through the assessment of clinically significant abnormalities in safety laboratory parameters, ECG findings, and vital signs.
Time frame: Up to week 52
D2TRA: Change from baseline in American College of Rheumatology (ACR) response criteria
Assessment of absolute values and change from baseline using a validated functional assessment tool that incorporates patient-reported measures of physical function and clinician-reported evaluations of disease activity, joint involvement, and pain
Time frame: Week 4,8,12,24,38 and 52
D2TRA: Change from baseline in a disease activity score-28 C-reactive protein (DAS28-CRP)
Assessment of absolute values and change from baseline using a validated composite clinical disease activity score that incorporates clinician-reported joint assessments, patient-reported disease activity, and laboratory or physiological indicators of inflammation
Time frame: Week 4,8,12,38 and 52
D2TRA: Change from baseline in Health Assessment Questionnaire Disability Index
Assessment of absolute values and change from baseline in a standardised patient reported quality of life questionnaire evaluating overall disease impact
Time frame: Week 4,8,12,24,38 and 52
D2TRA: Change from baseline in Ultrasound Outcome Measure in Rheumatology (OMERACT) score
Changes in standardised imaging score assessing synovitis and synovial vascularity in predefined joint.
Time frame: Week 12 and 52
D2TRA: Clinical response status
Proportion of participants achieving predefined levels of disease activity improvements and functional improvements
Time frame: Week 12 and 52
D2TRA & SSc: Use of additional background disease modifying therapy
Need for escalation of background disease modifying therapy above permitted baseline medication
Time frame: Week 12 and 52
D2TRA: Cumulative steroid exposure
Total systemic steroid dose received over specified intervals
Time frame: Baseline to week 12 and baseline to week 52
D2TRA: Ability to reduce glucocorticoid dose
Proportion of participants able to reduce systemic glucocorticoid use below a predefined daily threshold
Time frame: Up to week 52
D2TRA & SSc: Change from baseline in autoantibodies
Evaluation of change in blood levels of disease related autoantibodies
Time frame: Baseline to week 52
D2TRA & SSc: Presence of replication competent viral vector
Assessment of detectable replication competent viral vector in blood
Time frame: Week 52
SSc: Change From Baseline in a Modified Rodnan Skin Score (mRSS)
Assessment of absolute values and change from baseline in a validated, standardised skin involvement assessment score evaluating the extent and severity of cutaneous involvement in systemic sclerosis.
Time frame: Week 12,24,38 and 52
SSc: Change from baseline in Digital ulcers
Number of digital ulcers
Time frame: Week 12, 24, 38 and 52
SSc: Change From Baseline in a Standardised Lung Function Assessment Score
Assessment of absolute values and change from baseline using a validated, standardized lung function assessment score that evaluates pulmonary functional capacity
Time frame: Week 12, 24, 38 and 52
SSc: Change From Baseline in a Standardised High Resolution Computed Tomography (HRCT) Based Pulmonary Fibrosis Assessment Score
Assessment of absolute values and change from baseline in a validated, standardised HRCT based scoring system of interstitial lung disease, quantifying the extent and severity of pulmonary fibrosis.
Time frame: Week 24 and 52
SSc: Change From Baseline in a Standardised Positron Emission Tomography (PET) Based Pulmonary Fibrosis Assessment Score
Assessment of absolute values and change from baseline in a validated, standardised PET based assessment of fibroblast activation and fibrosis activity in predefined lung regions.
Time frame: Week 24 and 52
SSc: Change from baseline in Health Assessment Questionnaire Disability Index
Assessment of absolute values and change from baseline in a standardised patient reported quality of life questionnaire evaluating overall disease impact
Time frame: Week 12, 24, 38 and 52
SSc: Change From Baseline in the EUropean Scleroderma Trials And Research group (EUSTAR) Activity Index
Assessment of absolute values and change from baseline in a validated composite clinical disease activity assessment score used to evaluate systemic sclerosis disease activity.
Time frame: Week 12, 24, 38 and 52
SSc: Change From Baseline in the Sclerderma Clinical Trial Consortium (SCTC) Disease Damage Index
Assessment of absolute values and change from baseline in a validated disease damage assessment score used to evaluate longer-term organ involvement.
Time frame: Week 12, 24, 38 and 52
Change from Baseline in the European Alliance of Associations for Rheumatology Systemic Sclerosis Impact of Disease (EULAR ScleroID)
Assessment of absolute values and change from baseline in a validated patient-reported outcome questionnaire designed to measure the overall impact of systemic sclerosis on patients' daily function and quality of life.
Time frame: Week 12, 24, 38 and 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.